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ABSTRACT
Six colleagues working in the HIV ﬁeld were killed when their ﬂight en route to Kuala Lumpur was
shot down over the Ukraine. This report is drawn from the in memoriam keynote opening address
given at the 12th International AIDS Impact conference in Amsterdam in 2015. It highlights their
tangible and valued roles in the HIV response and looks forward to the road ahead. It describes
the ways in which we can build on their legacy to address current global challenges in HIV
prevention and treatment and to mobilise the intensiﬁed, focused resources that are needed to
turn the HIV epidemic on its head.
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Introduction
On 17 July 2014, Malaysia Airlines Flight 17, an inter-
national passenger plane ﬂying from Amsterdam to
Kuala Lumpur, crashed near Torez in Ukraine’s Donetsk
Oblast, 40 kilometres from the Ukraine–Russia border. It
had been shot down by a surface-to-air missile. All 283
passengers and 15 crew on board were killed. Among
them were 6 people en route to Melbourne, Australia
to attend AIDS 2014, the Twentieth International Con-
ference on AIDS.
A year later, when the Twelfth International AIDS
Impact conference, themed “We are our choices”,
opened in Amsterdam, a keynote address in memoriam
to these 6 colleagues highlighted their tangible, valued
roles in the HIV response and looked forward to the
road ahead. This short report drawn from the plenary
describes the ways in which we can build on their legacy
to address current global HIV challenges and mobilise
the intensiﬁed, focused resources that are needed to
turn the HIV epidemic on its head.
The six HIV colleagues who had their lives cut short
had contributed in diverse ways to the HIV response.
Lucie van Mens, a passionate advocate for women and
girls, promoted the female condom and safer working
conditions for sex workers in the Netherlands. Glenn
Thomas, media ofﬁcer at the World Health Organiz-
ation (WHO) for over a decade, was always keen to
tell the stories that really mattered. Martine de Schutter
was a key player in AIDS Action Europe for a decade
and the driving force behind the HIV/AIDS Civil Society
Forum. Pim de Kuijer, a skilled lobbyist for AIDSfonds,
was a diplomatic activist who advocated for increased
resources for the Global Fund. Jacqueline van Tongeren,
Director of Communications at the Amsterdam Institute
for Global Health and Development, was renowned for
her warmth, dedication, aesthetic taste, and invaluable
emotional intelligence. Joep Lange, a Dutch HIV clini-
cian scientist who had argued in 1995 that combining
at least three antiretroviral drugs was essential for sus-
tained, effective treatment without drug resistance, was
a former President of the International AIDS Society
who challenged group think and was renowned for his
activism for treatment access in resource-limited
settings.
Many of us moved from experiencing an acute and
searing sense of loss, through anger and disbelief, to
being inspired by their stories and demonstrated com-
mitment to HIV. Now, it is time to ﬁnd ways to build
on their legacy to complete the task of ending AIDS as
a public health threat by 2030 (Piot et al., 2015). Ten
indicators of global progress are tracking progress
towards this goal (Table 1) (WHO, 2015b) and
two main cascades, one in prevention (McNairy &
El-Sadr, 2014) and one in treatment (Bärnighausen,
2015), are the focus of concerted action to achieve
impact over the short-term and for a sustained effective
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response. Innovative research to ﬁnd a cure (Lewin,
2013) and create an efﬁcacious vaccine (Burton et al.,
2012; Nabel, 2013) holds hope for the long term.
Ramping up HIV prevention
Every one of the 2 million people who newly acquired
HIV infection in 2014 will require antiretroviral treat-
ment (ART) for life. Reducing risk now is critical to
stem the tide of HIV transmission and subsequent
ART need. The HIV epidemic is not static: some
countries have experienced important declines in the
numbers of new infections while others, such as Uganda,
have seen increased HIV incidence (UNAIDS, 2015b).
Striking outbreaks of HIV infection linked to the use of
non-sterile injecting equipment have occurred in Greece
(Saraﬁs & Tsounis, 2014) and Indiana, USA (Morbidity
and Mortality Weekly Report [MMWR], 2015), while
HIV incidence continues to increase in Russia (Russian
HIV-Aids epidemic worsening under Kremlin policies,
says expert, 2015).
The prevention cascade or continuum begins with
risk identiﬁcation to facilitate stratiﬁcation for tailored
counselling and provision of prevention services. These
may include voluntary medical male circumcision
(VMMC) for men living in areas of high heterosexual
transmission; male and female condoms; pre-exposure
prophylaxis (PrEP) with daily, intermittent, or event-dri-
ven use of pills for men and women at substantial risk of
HIV exposure; sterile injecting equipment for people
who inject drugs; and other prevention modalities. Con-
ducting outreach, supporting adherence, and encoura-
ging regular HIV testing and counselling; engaging
communities for social and sexual norm changes; and
implementing social protection and other programmes
that address the structural determinants of risk, such as
gender disparities (Jewkes, Dunkle, Nduna, & Shai,
2010) and the need for drug law reform (‘International
Drug Policy Consortium’, 2015), are all key components
of effective combination HIV prevention (Hankins & de
Zalduondo, 2010). For example, a new initiative in 10
countries in sub-Saharan Africa called the DREAMS
partnership (Determined, Resilient, Empowered, AIDS-
free, Mentored, Safe lives) focuses on empowering
young women and girls and reducing risk in them and
their sexual partners (DREAMS: Working Together for
an AIDS-free Future for Girls, 2015).
Signiﬁcant progress has been made in the scale-up of
VMMC, with over 10 million procedures performed in
priority countries of sub-Saharan Africa since 2008
(UNAIDS, 2015a); however, promising antiretroviral
(ARV) prevention faces several implementation chal-
lenges. Oral PrEP was approved in the USA more than
three years ago (FDA, 2012) and the World Health
Organisation has published guidelines (WHO, 2012)
(WHO, 2013) but thus far only France (ANRS, 2015),
South Africa (Medicines Control Council, 2015), and
Kenya (Gilead Sciences, Inc., 2015) have taken regulatory
or other action to ensure access for those at highest risk.
With trials underway of ARV-containing vaginal rings
(Microbicide Trials Network, n.d.) (International Part-
nership for Microbicides, n.d.), long-acting injectable
formulations (Spreen et al., 2014), and rectal microbi-
cides (Microbicides Trials Network, n.d.), it is critical
that steps be taken now to prevent similar delays in
ensuring access to any product proven effective. Trials
of broadly neutralising human monoclonal antibody
injections are underway (Ledgerwood et al., 2015), as
well as clade-speciﬁc vaccine trials following up on the
RV144 HIV vaccine trial (Rerks-Ngarm et al., 2009),
and these too require anticipatory preparation to make
them rapidly available in the event of proven efﬁcacy.
Treatment for all people living with HIV
The goals for strengthening the treatment cascade laid
out in the UNAIDS Fast Track Initiative are 90–90–90
by 2020 and 95–95–95 by 2030 (UNAIDS, 2014a). The
short-term objective means that 90% of people living
with HIV know their HIV status, 90% of people who
know their HIV status are on ART, and 90% of people
on ART are virally supressed. This translates into 73%
of all people living with HIV being virally suppressed.
Viral suppression is key not only for individual clinical
beneﬁt but also for prevention, reducing HIV trans-
mission by 96% (Cohen et al., 2011). The recent results
of the Temprano (The TEMPRANO ANRS, 12136
Table 1. Ten Global Strategic Information Indicators.
1. Epidemiology: Number and percentage of people living with HIV
2. Domestic ﬁnance: Per cent of HIV response ﬁnanced domestically
3. Prevention by key populations:
a. Sex workers: per cent condom use with most recent client
b. Men who have sex with men: per cent condom use at last anal sex with a
male partner
c. People who inject drugs: needle-syringes distributed per person
d. General population: per cent of women and men who had more than
one partner in the past 12 months who used a condom during their last
sexual encounter
4. Knowing HIV status: Number and proportion of people living with HIV who
have been diagnosed
5. Linkage to care: Number and proportion of people living with HIV who are
receiving HIV care (including ART)
6. Currently on ART: Number and percentage of people living with HIV
receiving ART
7. ART retention: Number and percentage of people living with HIV who are
retained on ART 12 months after initiation (and 24, 36, 48, and 60 months)
8. Viral suppression: Number and percentage of people on ART who have
suppressed viral load
9. HIV-related deaths: Number of HIV-related deaths per 100,000 population
10. New infections: Rate of new infections per 1000 uninfected population
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Study Group, 2015) and START (Lundgren et al., 2015)
trials conﬁrmed the clinical beneﬁt for individuals of
early treatment and the WHO has released preliminary
guidelines recommending that all people living with
HIV should be offered ART regardless of their CD4
count, a measure of immune suppression (WHO,
2015a).
Signiﬁcant gaps exist in country progress towards 73%
viral suppression. Switzerland, Australia, UK, Denmark,
the Netherlands, Rwanda, and France already have more
than 50% of their people living with HIV achieving viral
suppression. Trailing behind are the USA (30%), Africa
(29%), Russia (9%), and Cambodia (2%) (Hill, 2015).
The biggest gap is in knowledge of HIV status. Strategies
to increase HIV testing uptake include community
approaches, couples counselling and testing, provider-
initiated offers of HIV testing, and self-testing (WHO,
2015c). Linking those who test HIV-positive into care
quickly and effectively will reduce loss to follow-up of
people who know their HIV status. To ensure that people
achieve and are able to sustain their viral suppression,
essential community and peer support complements
health service adherence counselling, but equally impor-
tant are avoiding drug stock outs and managing ﬁrst-line
regimens well to avoid drug resistance.
Progress in the elimination of paediatric HIV has
been remarkable with a 43% decline since 2009 in new
HIV infections among children in 21 priority countries
(UNAIDS, 2014b). With the B+ treatment strategy,
that is, starting pregnant women on ART for life, now
recommended by WHO (World Health Organization,
2015a), the decline in paediatric infections is set to accel-
erate while maternal survival increases.
Stigma and discrimination continue to impede both
prevention and treatment programme effectiveness
worldwide, most markedly with respect to men who
have sex with men, people who inject drugs, and sex
workers. Legislative and policy changes are urgently
needed to underpin improvements in public attitudes
towards these key populations.
Financing the response
New strategies to fast track the HIV response require
effective use of existing resources and increased invest-
ment over the short term to reap the beneﬁts of averted
HIV treatment costs in the future. Funding for HIV pla-
teaued and then declined after the global economic cri-
sis. Recently it began to rise but, after adjusting for
inﬂation and exchange rate changes, the increase
between 2013 and 2014 was marginal (1%) (Kates, Wex-
ler, & Lief, 2015). Encouragingly, the proportion of HIV
expenditure from domestic resources has increased
steadily over the last 15 years. In 2005, bilateral and mul-
tilateral sources accounted for 69% of all HIV-related
spending but by 2014, domestic sources in low- and
middle-income countries had increased to 57%
(UNAIDS, 2015b). Nonetheless, half of Caribbean
region countries remain dependent on external sources
for 75–100% of their HIV treatment budget (McLean,
2015) and 73% of all HIV expenditure in Kenya is sup-
ported by external resources (Muchiri, 2015). This is not
simply a ﬁnancial issue; governance concerns are raised
when the survival of so many citizens depends on exter-
nal funding.
Standard ﬁscal space analyses suggest that possible
strategies to increase HIV funding include economic
growth, improved tax administration, reprioritisation,
development assistance, innovative ﬁnancing, external
borrowing, earmarked resources, and efﬁciency gains
in HIV service delivery and broader development pro-
grammes (Vassall, 2015). Investment and taxes in poor
countries can matter as much, if not more, as develop-
ment aid (Gates, 2015) but taxation systems need con-
siderable investment themselves. In 2013, tax revenue
constituted almost 34% of gross domestic product in
rich countries, compared to under 13% in poor countries
(‘Beyond aid: Financing Development’, 2015). Efﬁciency
gains can be made, both in allocative and technical efﬁ-
ciency but both domestic and bilateral/multilateral
investment can and must be increased and prioritised
to those areas, populations, and services where they
will have the greatest impact.
Conclusion
An estimated 30 million HIV infections were averted
between 2000 and 2014 as a result of ART roll-out and
effective prevention (UNAIDS, 2015b). The task now is
to end AIDS as a public health threat by 2030 as part
of the post-2015 development agenda. The UNAIDS-
Lancet Commission sets out seven key recommendations
to defeat AIDS and advance global health: expand
HIV prevention and treatment access, uphold human
rights, ramp up funding, ensure accountability,
strengthen leadership and community engagement,
invest in research and innovation, and promote multi-
stakeholder governance to address determinants of
health (Piot et al., 2015).
Business as usual will see the HIV epidemic with us
for decades and decades to come. The choice is clear.
We must, as Joep Lange often said, ‘Be creative and
think big to tackle the real problems’. HIV in the
twenty-ﬁrst century remains a very real problem.
Inspired by the memories of the tasks left undone by
the untimely deaths of our colleagues, we need to move
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forward with resolve, dedication, inspiration, passion,
and commitment to engage others and mobilise the
necessary ﬁnancial and human resources to ﬁnish the
task ahead.
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